Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs

Shrestha, Roman; DiDomizio, Elizabeth; Kim, Rayne S.; Altice, Frederick L.; Wickersham, Jeffrey A.; Copenhaver, Michael

doi:10.1016/j.jsat.2020.108058

Cited by 31 publications

(23 citation statements)

References 55 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study drew its sample from a parent study that recruited 234 patients from a methadone clinic to assess their preference for various HIV prevention strategies, as described in a previous study ( Shrestha et al, 2020 ). Individuals were eligible for the parent study if they were: a) 18 years or older; b) self-reported HIV-uninfected or had unknown HIV status; c) reported drug- or sex-related HIV risk behaviors in the past 6 months; d) met Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for OUD; e) receiving MOUD (i.e., methadone); and f) able to understand, speak, and read English.…”

Section: Methodsmentioning

confidence: 99%

Differential impacts of COVID-19 across racial-ethnic identities in persons with opioid use disorder

Mistler

Sullivan

Copenhaver

et al. 2021

Journal of Substance Abuse Treatment

Self Cite

View full text Add to dashboard Cite

Objective The COVID-19 pandemic has exacerbated health disparities, particularly among at-risk people with opioid use disorder (OUD). We sought to characterize the direct and indirect impacts of COVID-19 on this group to understand how the pandemic has affected this group, this group's public health response to COVID-19, and whether there were differences by race/ethnicity. Methods This study recruited its sample from a drug treatment setting in the northeast region of the United States. We surveyed 110 individuals on methadone as treatment for OUD and assessed COVID-19-related impacts on their health behaviors and other indices of social, physical, and mental well-being, including sexual health behaviors, substance use, mental health status, health care access, income, and employment. Results Our findings highlight overall increases in depression, anxiety, loneliness, and frustration among the sample of people with OUD; the study also observed decreases in financial stability. Significant differences between groups indicated a greater financial burden among racial-ethnic minorities; this subgroup also reported greater direct adverse effects of COVID-19, including being more concerned about contracting COVID-19, not being able to get a COVID-19 test, and knowing someone who had died from COVID-19. A greater proportion of Whites indicated increases in alcohol consumption and non–prescription drug use than did racial-ethnic minorities. Conclusions Treatment providers must be vigilant in managing direct and indirect outcomes of COVID-19 among people with OUD. Findings highlight the need to develop culturally competent, differentiated interventions in partnership with community-based organizations to meet the unique challenges that the COVID-19 pandemic presents for people in treatment for OUD.

show abstract

Section: Methodsmentioning

confidence: 99%

Differential impacts of COVID-19 across racial-ethnic identities in persons with opioid use disorder

Mistler

Sullivan

Copenhaver

et al. 2021

Journal of Substance Abuse Treatment

Self Cite

View full text Add to dashboard Cite

show abstract

“…Likewise, in a sample of 400 individuals enrolled in a methadone program in New Haven, Connecticut (CT), those with moderate to severe depression were more likely to be willing to use PrEP compared with those with no to mild depression [ 46 ]. However, in a study involving 234 individuals enrolled in a methadone program in New Haven, CT, depression was not correlated with willingness to use LAI-PrEP [ 45 ].…”

Section: Depressionmentioning

confidence: 99%

A Scoping Review Investigating Relationships between Depression, Anxiety, and the PrEP Care Continuum in the United States

Miller

Harrison

Sanasi-Bhola

2021

IJERPH

View full text Add to dashboard Cite

Men who have sex with men and transgender women in the United States are at increased risk for HIV and may benefit from pre-exposure prophylaxis (PrEP), a once-a-day pill to prevent HIV. Due to stigma and discrimination, sexual and gender minority (SGM) populations are also at risk for depression and anxiety. This scoping review sought to identify literature addressing relationships between the PrEP care continuum, depression, and anxiety among SGM individuals and others at high risk for HIV. We conducted a systematic review of four databases (i.e., PubMed, PsycInfo, Web of Science, Google Scholar) and identified 692 unique articles that were screened for inclusion criteria, with 51 articles meeting the final inclusion criteria. Data were extracted for key study criteria (e.g., geographic location, participant demographics, study design, main findings). Results suggest that while depression and anxiety are not associated with PrEP awareness or willingness to use, they can be barriers to seeking care and to PrEP adherence. However, empirical studies show that taking PrEP is associated with reductions in anxiety. Findings suggest the need to implement mental health screenings in PrEP clinical care. In addition, addressing systemic and structural issues that contribute to mental health disorders, as well as PrEP-related barriers, is critical.

show abstract

“…PrEP is a highly effective oral antiretroviral medication taken daily by people who are HIV-negative to prevent acquiring HIV (Anderson et al, 2012). Uptake of PrEP is low in general among populations who could benefit from biobehavioral prevention, but is especially low among people who inject drugs (Guise et al, 2017;Shrestha et al, 2020;.…”

Section: Introductionmentioning

confidence: 99%

Pre-exposure prophylaxis awareness, acceptability and potential stigma among medical and non-medical clinic staff in methadone treatment settings in northern New Jersey: The key role of non-medical staff in enhancing HIV prevention

Jaiswal

Dunlap

Griffin

et al. 2021

Journal of Substance Abuse Treatment

View full text Add to dashboard Cite

Background: HIV prevention is needed among people who use drugs (PWUD) due to mixing sex and drugs, selling/trading sex, and/or injecting drugs. Pre-exposure prophylaxis (PrEP) is an extremely effective biomedical HIV prevention strategy, but uptake remains low among communities most in need of HIV prevention, including PWUD. Previous studies have found that providers are less willing to prescribe PrEP to PWUD, yet PWUD express high levels of PrEP acceptance. More research is needed to understand how people who provide substance use treatment services think about PrEP to maximize this biomedical prevention strategy. Methods:The study conducted semistructured interviews with 29 staff members in two methadone clinic settings in urban northern New Jersey. Staff members included medical providers, methadone counselors, intake coordinators, front desk staff, lab technicians, security guards, and administrative/leadership personnel.

show abstract

Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs

Cited by 31 publications

References 55 publications

Differential impacts of COVID-19 across racial-ethnic identities in persons with opioid use disorder

Differential impacts of COVID-19 across racial-ethnic identities in persons with opioid use disorder

A Scoping Review Investigating Relationships between Depression, Anxiety, and the PrEP Care Continuum in the United States

Pre-exposure prophylaxis awareness, acceptability and potential stigma among medical and non-medical clinic staff in methadone treatment settings in northern New Jersey: The key role of non-medical staff in enhancing HIV prevention

Contact Info

Product

Resources

About